Clever Leaves Expands in Brazil Through Multi-Year Supply Agreement with GreenCare

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Clever Leaves International Inc. ("Clever Leaves"), a leading multi–national operator and licensed producer of pharmaceutical–grade cannabinoids, announced today that it has entered into a commercial agreement with GreenCare, a leading pharmaceutical company in education and medicine, access, and distribution of products in the Brazilian cannabinoids market, to license and distribute certain Clever Leaves' white label finished cannabis–derived products. The products that will be delivered to GreenCare will be manufactured in Clever Leaves' EU–GMP certified facilities in Colombia.

The three–year agreement provides that GreenCare will purchase at least $4M of product from Clever Leaves, and $2M was paid to Clever Leaves upon the execution of the contract. This type of agreement is a significant milestone in Latin America for cannabinoid products, and it could serve as a guide for additional supply partnerships that may be struck in the region going forward. Under the agreement, Clever Leaves will provide a territory–exclusive, patient–ready CBD–dominant product that will be exported to Brazil and registered in accordance with the Brazilian health regulatory agency's (ANVISA) regulations. The initial CBD–dominant product that will be shipped by Clever Leaves will be commercialized and distributed by GreenCare to pharmacies and other authorized pharmaceutical channels in the country. GreenCare has committed to perform clinical trials on the initial product, and the parties anticipate that the first commercial shipment under the agreement will reach the Brazilian market by second quarter of 2021.

"This partnership with Clever Leaves reinforces our commitment to offering solutions in the Brazilian market based on quality, safety and efficacy. It will allow us to expand a portfolio of reliable and internationally recognized products, ensuring that our investments in education and built relationships with the most respected doctors in the country are validated by the best available alternatives in cannabinoid treatment in Brazil," says Martim Prado Mattos, CEO of GreenCare.

“As the largest potential medical cannabis market in Latin America, Brazil represents an incredible market opportunity for Clever Leaves' licensed products. GreenCare is an ideal partner for Clever Leaves to enter Brazil, as they offer the critical experience and knowledge of the commercial dynamics in Brazil across the medical and pharmaceutical communities," said Kyle Detwiler, CEO of Clever Leaves. "The execution of this agreement provides Clever Leaves with a near–term revenue opportunity and is a display of confidence in the quality of our operations and our ability to deliver."

"This is a major milestone for Clever Leaves, as we pursue new commercial partnerships and navigate an evolving global medical cannabis marketplace," said Andrs Fajardo, President of Clever Leaves. "Our premium cannabinoid products, EU GMP certified production practices, and pharmaceutical stability data generated specifically for the Brazilian tropical conditions, coupled with GreenCare's access to important distribution channels and insight into doctors' and patients' needs, will set a new standard for accessibility, quality and value for Brazil."

Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including the highly coveted European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by INVIMA, and Good Agricultural and Collecting Practices (GACP) Certification. Also, in August 2020, Clever Leaves was granted a provisional license in Portugal from Infarmed "" the Portuguese health authority "" that allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes.

Clever Leaves recently announced that it amended its definitive agreement with Schultze Special Purpose Acquisition Corp. (Nasdaq: SAMA, SAMAW, and SAMAU) ("SAMA"), pursuant to which a newly formed holding company, Clever Leaves Holdings Inc. ("Holdco") will acquire SAMA and Clever Leaves (the "Business Combination"). The transaction is expected to close in the fourth quarter of 2020, with Holdco anticipated to become a Nasdaq–listed public company trading under the ticker symbol "CLVR”.

About Clever Leaves International Inc.
Clever Leaves is a multi–national cannabis company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large–scale cultivation and pharmaceutical–grade processing as the cornerstones of its global cannabinoid business. With operations and investments in Canada, Colombia, Germany, Portugal, and the United States, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry's leading global cannabinoid companies recognized for its principles, people, and performance while fostering a healthier global community.

About GreenCare

Founded in 2018, GreenCare has the mission to offer legal, safe and effective cannabinoid based products to the health and wellness segments of the Brazilian market.

With a strategy focused on continuous medical education, scientific research and innovation, GreenCare offers high quality products, providing strong support to doctors, patients and consumers. Holding thousands of face–to–face medical visits or virtual interactions every month, GreenCare has the highest capabilities among health professionals from the most varied clinical specialities including neurology, rheumatology, psychiatry, gynaecology, among others.

GreenCare believes in the potential of medicinal cannabis and in the countless benefits of its derived products for patients and their families. The company is continually expanding its portfolio of cannabis derived products to quickly meet the different needs of doctors, patients and consumers looking for innovative solutions in medical treatment and wellness care.

One of the leaders in sales and access in the Brazilian market, GreenCare has as its controlling shareholder, one of the most important global funds of venture capital specialized in cannabis businesses, Greenfield Global Opportunities, which has investments in 16 companies, established in 6 different countries.

About Schultze Special Purpose Acquisition Corp.
Schultze Special Purpose Acquisition Corp. (Nasdaq: SAMA, SAMAW, and SAMAU) is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. SAMA's sponsor is an affiliate of Schultze Asset Management, LP, an alternative investment management firm founded in 1998 that focuses on distressed, special situation and event–driven securities and has invested over $3.2 billion since inception with a notable track–record through its active investment strategy. SAMA itself is backed by an experienced team of operators and investors with a successful track–record of creating material value in public and private companies.

Additional Information and Where to Find It
In connection with the Business Combination, Holdco has filed a Registration Statement on Form S–4 (the "Registration Statement") with the Securities and Exchange Commission ("SEC") which includes a prospectus with respect to Holdco's securities to be issued in connection with the Business Combination and a proxy statement with respect to SAMA's stockholder meeting at which SAMA's stockholders will be asked to vote on the proposed Business Combination. SAMA, Clever Leaves and Holdco urge investors, stockholders and other interested persons to read the Registration Statement, including the proxy statement/prospectus contained therein, as well as other documents filed with the SEC, because these documents contain important information about the Business Combination. Following the Registration Statement having been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to stockholders of SAMA as of a record date to be established for voting on the Business Combination. SAMA's stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Schultze Special Purpose Acquisition Corp, 800 Westchester Avenue, Suite 632, Rye Brook, New York 10573; e–mail: These documents, once available, can also be obtained, without charge, at the SEC's web site (

Participants in Solicitation
SAMA, Clever Leaves, Holdco and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of SAMA stockholders in connection with the Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SAMA's stockholders in connection with the Business Combination is set forth in the preliminary proxy statement/prospectus contained in the Registration Statement, and will also be included in the definitive proxy statement/prospectus for the Business Combination when available. Information concerning the interests of SAMA's and Clever Leaves' participants in the solicitation, which may, in some cases, be different than those of SAMA's and Clever Leaves' equity holders generally, is also set forth in the proxy statement/prospectus contained in the Registration Statement, and will also be included in the definitive proxy statement/prospectus for the Business Combination when available.

Forward Looking Statements
This press release includes forward–looking statements that involve risks and uncertainties. Forward–looking statements are statements that are not historical facts and may be identified by the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). Such forward–looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward–looking statements. Factors that may cause such differences include, without limitation, SAMA's and Clever Leaves' inability to complete the transactions contemplated by the Business Combination; matters discovered by the parties as they complete their respective due diligence investigation of the other; the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by SAMA stockholders and the ability to close the private placement with certain institutional investors; the ability to meet Nasdaq's listing standards following the consummation of the Business Combination; costs related to the Business Combination; expectations with respect to future operating and financial performance and growth, including when Clever Leaves or Holdco will become cash flow positive; the timing of the completion of the Business Combination; Clever Leaves' ability to execute its business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; global economic conditions; geopolitical events, natural disasters, acts of God and pandemics, including, but not limited to, the economic and operational disruptions and other effects of COVID–19; regulatory requirements and changes thereto; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC. Other factors include the possibility that the proposed transaction does not close, including due to the failure to receive required security holder approvals or the failure to satisfy other closing conditions. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in the Registration Statement, including the proxy statement/prospectus included therein. All subsequent written and oral forward–looking statements concerning SAMA, Clever Leaves or Holdco, the transactions described herein or other matters and attributable to SAMA, Clever Leaves, Holdco or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made. Each of SAMA, Clever Leaves and Holdco expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Press contacts:
McKenna Miller
KCSA Strategic Communications

Diana Sigenza
Strategic Communications Director

Fbio Pimentel
GreenCare Strategic Communication

Investor inquiries:
Raphael Gross

SNOMED CT supports New Zealand’s Canterbury District Health Board realize vision of a data driven, connected and integrated health system

LONDON, Nov. 23, 2020 (GLOBE NEWSWIRE) — SNOMED International has released a series of videos that demonstrate the value that a healthcare system is deriving from implementing and using SNOMED CT, the world's most comprehensive clinical terminology.

The first chapter of the SNOMED CT Value Series, which focuses on New Zealand's Canterbury District Health Board (CDHB), highlights the advances the organization has made in realizing its vision of a connected, integrated system that supports the country's Healthy Ageing strategy and enables it to better serve its population. Acting Executive Director Planning, Funding and Decision Support, Ralph La Salle offers that "an integrated health system is essential for the health outcomes of the Canterbury population and quality data with thorough analysis leads to shared clinical insights and new ways of working collectively to optimise this integration."

Carolyn Gullery, who at the time of filming was the Executive Director, Planning, Funding and Decision Support for the CDHB, said New Zealand's commitment to becoming a SNOMED International Member in 2007 was the beginning of a positive change for a healthcare system that was, like so many others across the globe, under extreme financial and performance–related pressure. She explains that in 2007, while its primary care system was thriving, its hospital system was struggling. Canterbury needed a better picture of its current situation and a way to predict the future needs of its 578,000 residents.

Harnessing the power of data analytics
Key to that goal, she noted, was the ability to use data and analytics to understand why people were ending up in the health system, who they were and how to intervene more effectively to reduce the demand on the system and provide better care for patients. By using SNOMED CT as part of its core infrastructure, and its Healthcare Analytics Solution (HCAS), a software tool that applies natural language processing to the unstructured text–based data in a clinical record, the health boards were able to code their existing data to SNOMED CT and then demonstrate to clinicians the power of using those codes to analyze that data. It is estimated that approximately 80 percent of health data is unstructured, and can represent text, photos, X–rays, voice/video recordings, slides and emails, among other types of health data.

By building a series of systems that act as an integrated health platform, CDHB managed to use the same number of beds in 2019 as it did in 2007 for a population that over 12 years had grown by 80,000. Canterbury representatives also observed a 30 percent lower emergency department use and a 30 percent lower acute medical admission rate than the national average, meaning New Zealanders are less likely to end up in the hospital in Canterbury than in any other part of the country.

Reducing manual labor for clinicians
According to Dr. Nigel Gilchrist, a Canterbury physician, the organization had also struggled to identify vertebral spine fractures and identify patients who may not have received care for those fractures. By using SNOMED CT to search 13,000 X–ray reports as part of a pilot project involving West Coast DHB patients, the organization found that one–third of relevant patients had been treated, another third had not, and the remaining third had been misclassified.

"We now identify over 200 new vertebral fractures every month," he explained. "SNOMED CT has enabled us to identify specific case mixes that would otherwise take someone a long time to do manually." In fact, the organization saved more than a year of a clinician's time.

Interoperability across platforms
Another benefit of using SNOMED CT is its interoperability across the healthcare district's best–of–breed applications. "We need to be sure we're speaking the same language when we use data, and if we move it around, it's got to mean the same thing in one place as in another," said Dr. Saxon Connor, a Canterbury physician.

Other Canterbury clinicians say they are most excited by SNOMED CT's ability to help two different clinical tools "" an electronic medical record system and a pathways tool "" talk to each other via a SNOMED CT code linked to diagnoses, and by the ability to search for pathways and find hierarchies.

"In the past, we had to go through our pathways manually and put keywords on them so people could find them, and with SNOMED we get all those synonyms for free," said Kieran Holland, Clinical Lead for New Zealand's HealthPathways Programme, an online clinical guidance tool. "It has improved the user search experience."

SNOMED CT: a piece of the digital health ecosystem as CDHB realizes multiple benefits

  • 30 percent lower emergency department use than the national average
  • 30 percent lower acute medical admission rate than the national average
  • Held 2019 bed use to same numbers as in 2007 while serving a population that had grown by 80,000
  • Identified vertebral fracture patients who had not received care or whose cases had been misclassified
  • Saved a year of clinician time by automating previously manual processes
  • Interoperable across best–of–breed system
  • Ability to link clinical tools via a SNOMED code
  • Ability to search for pathways and hierarchies and improved user search experience

There is more energy than ever in rolling out SNOMED CT as a key clinical information standard for an equitable New Zealand health and disability system, one that is data–driven and digitally enabled and SNOMED International's CEO, Don Sweete, recognizes the dedication of New Zealand's implementation efforts. "Canterbury is a great example of the breadth of maturity that SNOMED CT offers from data coding, data analysis, and ultimately the ability to apply artificial intelligence to already structured SNOMED CT data. It's an end to end example of the benefit of SNOMED CT."

New Zealand's focus over the next few years is on primary and community care, where users are migrating their systems from Read Codes to SNOMED CT as they introduce new models of care and supporting software.

Watch the Value Series to learn more about SNOMED CT and New Zealand, a founding SNOMED International Member represented by the Ministry of Health Manat Hauora.

About SNOMED International
SNOMED International is a not–for–profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation. Learn More…

Kelly Kuru
Chief Communications Officer
SNOMED International